Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MIP Diagnostics Limited develops synthetic affinity reagents, specifically Molecularly Imprinted Polymers (MIPs) and nanoMIPs, as antibody alternatives for diagnostics, research reagents, and industrial applications. Their platform focuses on robust polymers for harsh environments with long shelf life, targeting peptides, proteins, drugs, and metabolites.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MIP Diagnostics Limited.